New Blood Test Detects Early Molecular Warning Signs of Ovarian Cancer

Ovarian cancer is often diagnosed at an advanced stage because early symptoms can be vague or easily mistaken for common digestive or urinary problems. Some aggressive ovarian cancers are believed to originate in the fallopian tubes before developing into invasive disease.

Serous tubal intraepithelial carcinoma, commonly called STIC, is a microscopic abnormality in the fallopian-tube lining that can act as a precursor to high-grade serous ovarian cancer.

The newly reported research investigated a blood-based approach that measures an RNA molecule called Tu-Stroma. Researchers examined whether this molecular signal could identify women with STIC before invasive cancer becomes apparent.

The reported test detected 92.3% of women with STIC and correctly identified 98.2% of healthy women in the study. The findings may be particularly relevant to women with inherited risk factors who face difficult decisions about preventive surgery.

However, the test is not yet established as a routine ovarian-cancer screening method. Larger studies will be required to validate its performance, assess false-positive results and determine whether its use improves patient outcomes.

The research represents a promising direction in early cancer detection, but it should not be interpreted as a clinically available replacement for established risk assessment and specialist care.